Matrix manufactures non- and cGMP Intermediates, and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical, biotech, and pharmaceutical industry.

The CDMO Business Unit (BU) operates out of Unit 10 in the Vizag Cluster, leveraging six state-of-the-art manufacturing facilities that are compliant with USFDA and EU GMP standards, EU GMP, and WHO certified manufacturing facilities across India, with expertise that spans a wide range of APIs, including complex molecules and high-potency ingredients.

Matrix offers comprehensive CDMO BU services to support pharmaceutical companies with custom synthesis, process development, and manufacturing, backed by a robust R&D team of > 275 scientists in our new R&D facility in Hyderabad.

Type of Drugs Manufactured:

Small Molecule

CDMO Services:

Drug Substance Manufacturing (API);Research & Development;Regulatory Services

No. of Manufacturing Facilities:

6-10

High Potent Products capabilities:

OEB >5

Facilities Locations:

South Asia

Regulatory Approvals for facilities:

FDA (United States);EMA (Europe);ISO;GMP;PMDA (Japan);NMPA (China);Health Canada;ANVISA (Brazil)